nVerses Capital’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,259
Closed -$212K – 159
2026
Q2
$212K Buy
+1,259
New +$187K 0.33% 176
2024
Q4
– Sell
-3,400
Closed -$392K – 560
2024
Q3
$392K Buy
+3,400
New +$466K 0.18% 177

Other funds holding NBIX

nVerses Capital's NBIX Position: Q3 2026 in Review

nVerses Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 1,259 shares — an estimated $212K sold.

nVerses Capital first reported a position in NBIX in Q3 2024 and held it in 2 quarters. The position peaked at $392K in Q3 2024. 760 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • nVerses Capital reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
  • nVerses Capital sold 1,259 Neurocrine Biosciences shares in Q3 2026, an estimated $212K.
  • nVerses Capital first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 2 quarters.
  • nVerses Capital's Neurocrine Biosciences position peaked at $392K in Q3 2024.
  • 760 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on nVerses Capital's 13F filing for Q3 2026.